Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › North Canton › NPI 1740234806
Physician

Ohio Rehab Center II, INC

Ohio Rehab Center II, INC was paid $1.05M by Medicaid between Jan 2018 and Dec 2024, across 48 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 45% of everything it billed.

33Billing provider infoOHIO REHAB CENTER II, INC
NORTH CANTON, OH 44720
33aNPI1740234806assigned 05/20/2006
28Total paid$1.05M
24GClaims149,239
24DCodes billed48
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Interventional Pain Medicine Physician providers in Ohio

Rank by total paid#2 of 24
Median peer was paid$20K
This provider vs. median52×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201813,772$157K
201926,252$154K
202015,346$153K
202131,322$211K
202223,617$147K
202321,291$120K
2024incomplete17,639$108K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 45% 21,293 19,031 $472K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 15% 5,857 5,128 $154K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 11% 3,435 2,996 $119K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 9.7% 1,910 1,599 $102K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 5.3% 1,509 1,294 $56K
20553 2.4% 1,113 957 $25K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2.2% 404 366 $23K
90837 Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient 2.1% 332 196 $22K
80364 1.4% 853 823 $15K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1.1% 866 751 $11K
93040 1.0% 1,502 1,292 $11K
64483 1.0% 176 160 $11K
36 more codes
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 296 $6K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 834 $5K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 533 $4K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 221 $3K
64484 <1% 58 $3K
94761 <1% 1,424 $2K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 162 $1K
96132 <1% 42 $1K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 2,636 $842.77
95886 <1% 25 $663.25
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,413 $547.86
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 136 $187.11
96138 <1% 39 $147.00
99442 <1% 18 $95.69
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 201 $55.19
A4550 Surgical trays <1% 1,564 $16.30
G9903 Patient screened for tobacco use and identified as a tobacco non-user 0% 11,228 $0.00
G9906 Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) 0% 1,660 $0.00
G8950 Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented 0% 8,775 $0.00
G9902 Patient screened for tobacco use and identified as a tobacco user 0% 7,714 $0.00
G8420 Bmi is documented within normal parameters and no follow-up plan is required 0% 4,534 $0.00
1036F 0% 6,213 $0.00
G8418 Bmi is documented below normal parameters and a follow-up plan is documented 0% 37 $0.00
G9367 At least two orders for high-risk medications from the same drug class 0% 64 $0.00
G8417 Bmi is documented above normal parameters and a follow-up plan is documented 0% 11,863 $0.00
4004F 0% 8,812 $0.00
G8730 Pain assessment documented as positive using a standardized tool and a follow-up plan is documented 0% 4,475 $0.00
G8427 Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications 0% 20,177 $0.00
3288F 0% 1,029 $0.00
G9562 Patients who had a follow-up evaluation conducted at least every three months during opioid therapy 0% 3,072 $0.00
1124F 0% 1,522 $0.00
G8783 Normal blood pressure reading documented, follow-up not required 0% 5,571 $0.00
G9584 Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy 0% 2,438 $0.00
1100F 0% 128 $0.00
G9622 Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method 0% 355 $0.00
G9578 Documentation of signed opioid treatment agreement at least once during opioid therapy 0% 720 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCARR, JOSHUA (ADMIN)
Same official

Other billing entities under CARR, JOSHUA

Full network →
ProviderLocationPaid
MT. Gibborim, PLLCHurricane, UT$841.80

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.